Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
Sarah B. Mueller, Claire J. Detweiler, Anthony D. Sung, Vinod K. Prasad, Jennifer L. Saullo, Diana M. Cardona
Publikováno v:
Journal of Pediatric Hematology/Oncology. 40:e364-e368
Brincidofovir (CMX001) is an oral agent with activity against double-strand DNA viruses undergoing clinical trials in immunocompromised patients. We report a patient clinically diagnosed with brincidofovir-related gastrointestinal (GI) toxicity and h
Publikováno v:
Journal of Pediatric Hematology/Oncology. 39:e11-e14
Background β-thalassemia is the most common heredity disease in Iran. Regular blood transfusion is critical to sustain life and normal growth. Deferasirox is an oral chelator. One of the side effects of the deferasirox is proteinuria. Objectives Thi
Autor:
Amanda Sankar, Angela C. Weyand, Thomas F. Michniacki, Christie Atchison, Mary H. McGrath, Kelly Walkovich
Publikováno v:
Journal of Pediatric Hematology/Oncology. 43:e436-e437
Our report explores the complex role that nuclear factor-kappa B (NF-κB) plays in thrombosis formation, inflammation, and immunity; while additionally demonstrating that patients with NF-κB pathway pathogenic variants appear to carry a substantial
Publikováno v:
Journal of Pediatric Hematology/Oncology. 40:e266-e267
Publikováno v:
Journal of Pediatric Hematology/Oncology. 36:e460-e462
WOS: 000343045300014
PubMed ID: 24309614
Colchicine is a widely used alkaloid extract in children and adults for standard therapy and prophylaxis for amyloid deposition in different rheumatologic disorders. Colchicine intoxication is a rare
PubMed ID: 24309614
Colchicine is a widely used alkaloid extract in children and adults for standard therapy and prophylaxis for amyloid deposition in different rheumatologic disorders. Colchicine intoxication is a rare
Autor:
Allison A. King, Susan S. Hayashi, Roanne K. Karzon, Catherine M. Albert, Jennifer B. Dean, Robert J. Hayashi
Publikováno v:
Journal of Pediatric Hematology/Oncology. 30:130-134
Carboplatin is a well-established chemotherapeutic agent used to treat a variety of pediatric malignancies. Platinum analogues such as cisplatin are known to be ototoxic, but little is known regarding the ototoxicity of carboplatin. We performed a si
Autor:
Naoko Yasui, Satoshi Asanuma, Hideaki Sakata, Motohiro Kato, Katsuyoshi Koh, Nodoka Adachi, Ryoji Hanada
Publikováno v:
Journal of pediatric hematology/oncology. 36(4)
Cisplatin is an effective chemotherapeutic agent against pediatric cancers; however, ototoxicity is a concern. This study describes the frequency, severity, and clinical course of hearing loss in Japanese pediatric patients treated with cisplatin-bas
Publikováno v:
Journal of pediatric hematology/oncology. 36(2)
Lymphomas predominantly affect the lymph nodes but can present at unusual sites, which are termed as extranodal lymphomas. Involvement of the ocular adnexa is an extremely uncommon occurrence, which is usually seen in patients with non-Hodgkin lympho
Publikováno v:
Journal of pediatric hematology/oncology. 34(1)
Deferasirox (DFX) is a relatively new iron chelator approved by the US Food and Drug Administration for treatment of children >2 years of age. Prospective studies in Asian Indian children are limited. The β-thalassemia patients receiving regular tra
Publikováno v:
Journal of Pediatric Hematology/Oncology. 24:327-329
Anew case of cobalamin C disease associated with hemolytic-uremic syndrome (HUS) in the neonatal period is described. A 28-day-old boy presented with failure to thrive, hypotonia, pancytopenia, and features of HUS (microangiopathic hemolytic anemia,